Skip to content
DataLookout
Menu

LEAP2KIDSNCT07927140

The Efficacy and Safety of Venglustat Compared With Cerezyme in Pediatric Participants 2 to 11 Years of Age With Gaucher Disease Type 3 (GD3)

StatusNot Yet Recruiting
PhasePhase 3
SponsorSanofi
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Percent change from baseline in magnetic resonance imaging(MRI) spleen volume (in multiples of normal [MN]) at Week 52
Timeframe: at Week 52

Secondary (8)

Percent change from baseline in MRI liver volume (in MN) at Week 52
Change from baseline in hemoglobin level at Week 52
Percent change from baseline in platelet count at Week 52
Changes from baseline in Vineland Adaptive Behavior Scales III Adaptive Behavior Composite (ABC) score at Week 52
Change from baseline in Vineland Adaptive Behavior Scale (VABS) III motor skill score at Week 52
Show 3 moreShow less
Percent change from baseline in plasma glucosylceramide (GL-1), glucosylsphingosine (lyso-GL-1), and other potential biomarker levels to Week 52
Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs) and adverse events of special interest (AESIs)
Plasma venglustat Ctrough at prespecified visits

Arms and interventions

VenglustatExperimental

Oral venglustat QD for 52 weeks in an open-label design for Primary Treatment Period followed by oral venglustat QD for 52 weeks in the Extension Treatment Period

CerezymeActive comparator

Primary Treatment Period: Cerezyme infusion every 2 weeks for 52 weeks

Drugs: Venglustat, Imiglucerase